Non-prescribed antibiotic use for children at community levels in low- and middle-income countries: a systematic review and meta-analysis.
Antibiotic use
Children
Community-level
Low- and middle-income countries
Non-prescribed
Journal
Journal of pharmaceutical policy and practice
ISSN: 2052-3211
Titre abrégé: J Pharm Policy Pract
Pays: England
ID NLM: 101627192
Informations de publication
Date de publication:
30 Sep 2022
30 Sep 2022
Historique:
received:
25
05
2022
accepted:
20
09
2022
entrez:
30
9
2022
pubmed:
1
10
2022
medline:
1
10
2022
Statut:
epublish
Résumé
Non-prescribed antibiotic use is an emerging risky practice around the globe. An inappropriate use involving nonprescription access is one cause of the rapid increase in antibiotic resistance. Children commonly encounter many self-limiting illnesses for which they frequently use antibiotics without prescription. However, no specific and conclusive evidence exists to inform actions against this unsafe practice. We thus aimed to estimate the pooled proportion of non-prescribed antibiotic use for children at community levels in low- and middle-income countries. A systematic search of records was conducted from PubMed/Medline, Embase, Scopus, CINAHL, and Google scholar. Eligible English-language publications were original articles which reported on community-based non-prescribed antibiotic use for children and conducted in low- and middle-income countries. Study features and the number of antibiotics used without prescriptions were extracted and pooled for effect sizes employing a random-effects model. The pooled proportion of non-prescribed antibiotic use was estimated as a percentage. In this analysis, we included a total of 39 articles consisting of 40,450 participants. Of these, 16,315 participants used non-prescribed antibiotics. The pooled percentage for this use of non-prescribed antibiotics was 45% (95% CI: 40-50%). The estimate was considerably higher in studies involving simulated patient methods (56%; 95% CI: 49-62%) than those studies with community surveys (40%; 95% CI: 34-46%) (P = 0.001). It was also varied by the recall period of antibiotics use-56% (95% CI: 50-62%) for instantly observed practice, 36% (95% CI: 22-50%) for within two week recall, 35% (95% CI: 26-45%) for 1-6 months recall, and 46% (95% CI: 37-54%) for more than six months recall (P = 0.001). Primary access points for the non-prescribed antibiotic uses were retail drug outlets. We found that nearly half of the antibiotics used for children in community settings were without prescriptions. For these unsafe practices, caregivers accessed antibiotics mainly from drug outlets. Hence, context-specific educational and regulatory interventions at these outlets and the community levels are the first steps to improving antibiotic usage for children in low- and middle-income countries. CRD42021288971 (PROSPERO). https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021288971 .
Sections du résumé
BACKGROUND
BACKGROUND
Non-prescribed antibiotic use is an emerging risky practice around the globe. An inappropriate use involving nonprescription access is one cause of the rapid increase in antibiotic resistance. Children commonly encounter many self-limiting illnesses for which they frequently use antibiotics without prescription. However, no specific and conclusive evidence exists to inform actions against this unsafe practice. We thus aimed to estimate the pooled proportion of non-prescribed antibiotic use for children at community levels in low- and middle-income countries.
METHODS
METHODS
A systematic search of records was conducted from PubMed/Medline, Embase, Scopus, CINAHL, and Google scholar. Eligible English-language publications were original articles which reported on community-based non-prescribed antibiotic use for children and conducted in low- and middle-income countries. Study features and the number of antibiotics used without prescriptions were extracted and pooled for effect sizes employing a random-effects model. The pooled proportion of non-prescribed antibiotic use was estimated as a percentage.
RESULTS
RESULTS
In this analysis, we included a total of 39 articles consisting of 40,450 participants. Of these, 16,315 participants used non-prescribed antibiotics. The pooled percentage for this use of non-prescribed antibiotics was 45% (95% CI: 40-50%). The estimate was considerably higher in studies involving simulated patient methods (56%; 95% CI: 49-62%) than those studies with community surveys (40%; 95% CI: 34-46%) (P = 0.001). It was also varied by the recall period of antibiotics use-56% (95% CI: 50-62%) for instantly observed practice, 36% (95% CI: 22-50%) for within two week recall, 35% (95% CI: 26-45%) for 1-6 months recall, and 46% (95% CI: 37-54%) for more than six months recall (P = 0.001). Primary access points for the non-prescribed antibiotic uses were retail drug outlets.
CONCLUSIONS
CONCLUSIONS
We found that nearly half of the antibiotics used for children in community settings were without prescriptions. For these unsafe practices, caregivers accessed antibiotics mainly from drug outlets. Hence, context-specific educational and regulatory interventions at these outlets and the community levels are the first steps to improving antibiotic usage for children in low- and middle-income countries.
TRIAL REGISTRATION NUMBER
BACKGROUND
CRD42021288971 (PROSPERO). https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021288971 .
Identifiants
pubmed: 36180895
doi: 10.1186/s40545-022-00454-8
pii: 10.1186/s40545-022-00454-8
pmc: PMC9524137
doi:
Types de publication
Journal Article
Langues
eng
Pagination
57Informations de copyright
© 2022. The Author(s).
Références
BMJ. 2019 Jul 24;366:l4836
pubmed: 31340928
Antimicrob Resist Infect Control. 2020 Sep 7;9(1):150
pubmed: 32894189
Patient Prefer Adherence. 2020 Aug 19;14:1445-1453
pubmed: 32884246
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa048
pubmed: 32974610
Antibiotics (Basel). 2020 Apr 06;9(4):
pubmed: 32268530
CMAJ. 2007 Apr 10;176(8):1091-6
pubmed: 17420491
J Infect. 2019 Jan;78(1):8-18
pubmed: 29981773
Clin Microbiol Infect. 2021 Sep;27(9):1293-1300
pubmed: 33188934
Expert Rev Anti Infect Ther. 2019 Jun;17(6):459-466
pubmed: 31122087
Trop Med Int Health. 2015 Dec;20(12):1815-22
pubmed: 26376187
BMJ. 2015 Sep 16;351:h4718
pubmed: 26377337
Expert Rev Anti Infect Ther. 2019 Aug;17(8):621-634
pubmed: 31282277
Int J Infect Dis. 2017 Jul;60:83-87
pubmed: 28546075
Lancet. 2013 Apr 20;381(9875):1405-1416
pubmed: 23582727
J Clin Epidemiol. 2005 Aug;58(8):769-76
pubmed: 16086467
Antibiotics (Basel). 2021 Sep 24;10(10):
pubmed: 34680735
East Mediterr Health J. 2012 Jun;18(6):635-40
pubmed: 22888622
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2013;34(2):59-70
pubmed: 24280886
BMC Public Health. 2017 Sep 21;17(1):732
pubmed: 28934933
JMIR Med Educ. 2017 Apr 19;3(1):e7
pubmed: 28428160
Int J Environ Res Public Health. 2018 Jun 12;15(6):
pubmed: 29895758
Int J Pharm Pract. 2010 Dec;18(6):323-31
pubmed: 21054592
Infect Drug Resist. 2021 Mar 22;14:1129-1140
pubmed: 33790584
Int J Environ Res Public Health. 2021 Aug 04;18(16):
pubmed: 34444015
Int J Antimicrob Agents. 2016 Jun;47(6):490-4
pubmed: 27208900
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Eval Clin Pract. 2020 Feb;26(1):181-189
pubmed: 31111612
Semin Respir Crit Care Med. 2019 Aug;40(4):476-487
pubmed: 31585474
J Infect Dev Ctries. 2015 May 18;9(5):505-11
pubmed: 25989170
Pan Afr Med J. 2020 Apr 29;35:142
pubmed: 32655756
Antibiotics (Basel). 2020 Sep 12;9(9):
pubmed: 32932630
Antibiotics (Basel). 2021 Apr 22;10(5):
pubmed: 33922058
Panminerva Med. 2017 Sep;59(3):274
pubmed: 28665097
BMC Public Health. 2019 Nov 26;19(1):1560
pubmed: 31771536
Int J Antimicrob Agents. 2016 Jul;48(1):27-32
pubmed: 27318624
PLoS One. 2019 Aug 22;14(8):e0221452
pubmed: 31437215
Antibiotics (Basel). 2020 Nov 07;9(11):
pubmed: 33171743
Antimicrob Resist Infect Control. 2019 Jul 16;8:119
pubmed: 31346460
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
BMC Public Health. 2020 Jul 14;20(1):1103
pubmed: 32664902
Health Econ. 2003 Feb;12(2):125-38
pubmed: 12563660
J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6
pubmed: 16088799
Pediatr Infect Dis J. 2020 Nov;39(11):e359-e362
pubmed: 32773659
BMJ Open. 2021 Dec 14;11(12):e051372
pubmed: 34907055
J Health Serv Res Policy. 2002 Jan;7(1):51-61
pubmed: 11822262
BMJ. 2008 Apr 26;336(7650):948-9
pubmed: 18397947
Emerg Infect Dis. 2020 Jul;26(7):1517-1520
pubmed: 32568044
Antimicrob Resist Infect Control. 2017 Nov 07;6:112
pubmed: 29152233
BMJ Open. 2019 Dec 15;9(12):e033679
pubmed: 31843850
Lancet Reg Health West Pac. 2022 Apr 11;23:100447
pubmed: 35465041
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5527-32
pubmed: 27401572
Lancet Infect Dis. 2019 Dec;19(12):1345-1354
pubmed: 31588042
Res Synth Methods. 2021 Jan;12(1):55-61
pubmed: 32336025
BMC Public Health. 2019 Jun 10;19(1):726
pubmed: 31182071
PLoS One. 2018 Aug 16;13(8):e0201349
pubmed: 30114193
Int J Infect Dis. 2020 Apr;93:56-61
pubmed: 31982627
Antimicrob Resist Infect Control. 2017 Mar 24;6:30
pubmed: 28352463
Int J Infect Dis. 2017 Apr;57:3-12
pubmed: 28111172
J Infect Dev Ctries. 2020 Feb 29;14(2):129-137
pubmed: 32146446
Int J Evid Based Healthc. 2018 Dec;16(4):195-203
pubmed: 29621038
BMC Fam Pract. 2017 Mar 16;18(1):37
pubmed: 28302056
Pharmacy (Basel). 2020 Dec 13;8(4):
pubmed: 33322193
Trop Med Infect Dis. 2019 Feb 12;4(1):
pubmed: 30759811
Expert Rev Anti Infect Ther. 2022 Feb;20(2):315-321
pubmed: 34196261
Lancet Infect Dis. 2020 Feb;20(2):179-187
pubmed: 31843383
BMC Pediatr. 2022 Jun 1;22(1):322
pubmed: 35650548
Expert Rev Anti Infect Ther. 2021 Sep;19(9):1157-1164
pubmed: 33507127
Lancet. 1997 May 17;349(9063):1436-42
pubmed: 9164317
Health Technol Assess. 2003;7(41):1-90
pubmed: 14670218
PLoS One. 2019 Jun 19;14(6):e0218515
pubmed: 31216352
Pharm Pract (Granada). 2014 Jan;12(1):376
pubmed: 24644521
Microb Drug Resist. 2020 Sep;26(9):1063-1070
pubmed: 32182187
BMC Health Serv Res. 2008 Jun 06;8:123
pubmed: 18538009
Saudi Pharm J. 2018 Sep;26(6):780-785
pubmed: 30202217
BMC Public Health. 2021 Feb 25;21(1):406
pubmed: 33632193
Pediatric Health Med Ther. 2022 Mar 18;13:63-79
pubmed: 35340354
J Am Coll Emerg Physicians Open. 2021 Apr 29;2(2):e12432
pubmed: 33969344
Pediatric Health Med Ther. 2020 May 07;11:135-143
pubmed: 32440249
Arch Public Health. 2021 Jan 3;79(1):2
pubmed: 33390176
BMC Public Health. 2017 Apr 19;17(1):333
pubmed: 28420365
Expert Rev Anti Infect Ther. 2016 Sep;14(9):863-72
pubmed: 27351748
Int J Antimicrob Agents. 2021 Apr;57(4):106302
pubmed: 33588014
Infect Drug Resist. 2021 Feb 11;14:519-533
pubmed: 33603416
Antimicrob Agents Chemother. 2003 Feb;47(2):518-23
pubmed: 12543652
Front Public Health. 2022 Feb 09;9:770709
pubmed: 35223755
J Clin Epidemiol. 2021 Sep;137:209-217
pubmed: 33933579
Antibiotics (Basel). 2019 Apr 01;8(2):
pubmed: 30939797
Infect Drug Resist. 2019 May 17;12:1333-1351
pubmed: 31190922
Lancet Planet Health. 2018 Sep;2(9):e398-e405
pubmed: 30177008
Antimicrob Resist Infect Control. 2015 Dec 11;4:55
pubmed: 26693005
BMJ Open. 2017 Mar 2;7(3):e013190
pubmed: 28255093
BMC Public Health. 2022 Mar 7;22(1):459
pubmed: 35255863
Expert Rev Anti Infect Ther. 2018 Feb;16(2):163-172
pubmed: 29310469
J Antimicrob Chemother. 2017 Apr 1;72(4):1235-1242
pubmed: 28062684
PLoS One. 2020 Dec 10;15(12):e0243555
pubmed: 33301450
J Family Community Med. 2018 Jan-Apr;25(1):5-12
pubmed: 29386956
Antimicrob Resist Infect Control. 2021 Jan 14;10(1):13
pubmed: 33446266
BMC Public Health. 2015 Aug 01;15:742
pubmed: 26231758
Soc Sci Med. 2005 Jan;60(1):131-41
pubmed: 15482873
Int J Technol Assess Health Care. 2012 Apr;28(2):138-44
pubmed: 22559755
Lancet Glob Health. 2021 May;9(5):e610-e619
pubmed: 33713630
Bull World Health Organ. 2010 Dec 1;88(12):930-6
pubmed: 21124718
Trans R Soc Trop Med Hyg. 2020 Jun 1;114(6):401-407
pubmed: 32307551
Lancet Glob Health. 2020 Jun;8(6):e799-e807
pubmed: 32446345
J Glob Health. 2013 Jun;3(1):010403
pubmed: 23826507
Soc Sci Med. 1997 Nov;45(10):1465-82
pubmed: 9351137
PLoS One. 2019 Feb 28;14(2):e0212875
pubmed: 30818373
Vaccine. 2018 Dec 14;36(51):7780-7789
pubmed: 30007826
Glob Health Action. 2014 Oct 29;7:25473
pubmed: 25377331
Lancet Infect Dis. 2020 Feb;20(2):146-147
pubmed: 31843382
Int J Clin Pract. 2021 Jan;75(1):e13665
pubmed: 32772449
Public Health. 2019 Mar;168:92-101
pubmed: 30716570
J Invest Dermatol. 2016 Nov;136(11):e109-e114
pubmed: 27772550
J Clin Epidemiol. 2020 Nov;127:59-68
pubmed: 32679313
Int J Epidemiol. 2002 Feb;31(1):115-23
pubmed: 11914306
Ann Intern Med. 2019 Aug 20;171(4):257-263
pubmed: 31330541
Ther Clin Risk Manag. 2016 Apr 05;12:515-26
pubmed: 27103810
PLoS One. 2020 Sep 24;15(9):e0239388
pubmed: 32970720
PLoS One. 2020 Jun 23;15(6):e0235164
pubmed: 32574206
J Pharm Policy Pract. 2022 Sep 30;15(1):57
pubmed: 36180895
PLoS One. 2019 Aug 5;14(8):e0219097
pubmed: 31381611
PLoS One. 2021 Oct 4;16(10):e0257837
pubmed: 34607333
Int J Environ Res Public Health. 2018 Apr 05;15(4):
pubmed: 29621165
BMC Public Health. 2021 Jun 29;21(1):1254
pubmed: 34187421
Prev Sci. 2013 Apr;14(2):134-43
pubmed: 23479191
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
BMC Infect Dis. 2014 Feb 27;14:112
pubmed: 24576064